It has anti-inflammatory, antipyretic, analgesic effect. It belongs to the class of oxicams; enolovoy acid derivative. Meloxicam inhibits the synthesis of prostaglandins in inflammation to a greater extent than in the gastric mucosa and kidney, which is associated with relatively selective COX-2 inhibition.
In the appointment of high-dose, long-term use and individual andriol testosterone characteristics of the organism in relation to the selectivity of action of cyclooxygenase type 2 decreases.
The absorption from the gastrointestinal tract after oral administration – 89%. Food does not affect the absorption. The concentration in plasma is dose dependent.The average values of Cmax while taking 15 mg of the drug Mataram ® – 1.17 g / ml. The time to maximum concentration is between 4-6 hours. The equilibrium concentrations are reached after 3-5 days. Relationship to plasma proteins – 99%. It passes through the blood-tissue barrier, enters the synovial fluid. The volume of distribution is low, on average 11 l. Concentration in the synovial fluid – 50% of the plasma concentration. It is metabolized in the liver – to inactive metabolites.Displayed through the intestines and the kidneys (approximately equal proportions), in an unmodified form – 5% of the daily dose (in the intestines). The half – 20 hours. Plasma clearance – average of 8 ml / min (reduced in the elderly).
Rheumatoid arthritis; osteoarthritis; Ankylosing spondylitis (Bechterew’s disease) and other inflammatory and degenerative diseases of the joints, accompanied by pain syndrome.
Hypersensitivity to any component of the drug, as well as non-steroidal anti-inflammatory drugs other groups;
A history of bronchial asthma, urticaria, or acute rhinitis, provoked by taking aspirin or other NSAIDs;
The aggravation of gastric ulcer and 12 duodenal ulcer;
Severe hepatic impairment;
Severe heart failure;
Chronic renal failure patients who are not undergoing hemodialysis;
Gastrointestinal, cerebrovascular bleeding or other.
Children’s age (12 years), pregnancy, lactation.
The drug should be used with caution in elderly patients, in patients with erosive and ulcerative lesions of the gastrointestinal tract in history.
Pregnancy and lactation
Use during pregnancy is contraindicated.
In the period of lactation when using the drug should address the issue of termination of breastfeeding.
Dosing and Administration
Inside, during a meal, 1 time per day.
In rheumatoid arthritis and ankylosing spondylitis (ankylosing spondylitis), 15 mg / day, when a positive therapeutic effect, the dose can be reduced to 7.5 mg / day.
Osteoarthritis 7.5 mg / day, if necessary, increase the dose to 15 mg / day. The maximum daily dose of -15 mg.
The starting dose in patients with an increased risk of side effects is 7.5 mg / day. In patients with severe renal impairment on hemodialysis, the maximum daily dose of 7.5 mg. With low or moderate reduction of renal function (creatinine clearance for more than 25 ml / min), as well as in liver cirrhosis in stable clinical condition – dose adjustment is required.
From the digestive system: more than 1% – indigestion, including nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1% – transient increase in activity andriol testosterone of “liver” transaminases, hyperbilirubinemia, eructation, esophagitis, gastroduodenal ulcer, bleeding from the gastrointestinal tract (including hidden), stomatitis; less than 0.1% – gastrointestinal perforation, colitis, hepatitis, gastritis.
From the side of hematopoiesis: more than 1% – anemia; 0.1-1% – changes in blood counts, including leukopenia, tromotsitopeniya.
For the skin: more than 1% – itching, skin rash; 0.1-1% – urticaria; less than 0.1% -fotosensibilizatsiya, bullous rash, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis.
The respiratory system: less than 0.1% – bronchospasm.
From the nervous system: more than 1% – dizziness, headache; 0.1-1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.
Since the cardiovascular system: more than 1% – peripheral edema; 0.1-1% -increase in blood pressure, palpitations, “tides” of blood to the skin.
From the urinary system: 0.1-1% – hypercreatininemia and / or an increase in urea in blood serum; less than 0.1% – acute renal failure; connection with the intake of meloxicam is not installed – interstitial nephritis, albuminuria, hematuria.
From the senses: less than 0.1% – conjunctivitis, visual disturbances, including blurred vision.
Allergic reaction: less than 0.1% – angioedema, anaphylactoid / anaphylactic reactions.
Failure to comply with the recommended doses when taken orally, can cause drug overdose, manifested in increased side effects. Treatment: gastric lavage and symptomatic therapy. No specific antidotes and antagonists.
when taken concomitantly with others. Nonsteroidal anti-inflammatory drugs increases the risk of ulcerative lesions of the gastrointestinal tract and gastrointestinal bleeding.
Meloxicam increases the concentration of lithium (Li +) in the plasma.
Reduces the effectiveness of intrauterine contraceptive, antihypertensive drugs.
Indirect anticoagulants, ticlopidine, heparin, thrombolytics increase risk of bleeding. Methotrexate amplifies mielodepressivnoe action without sharing recommended dose methotrexate 15mg a week.
Diuretics increase the risk of renal dysfunction.
Cyclosporin enhances nephrotoxicity.
Cholestyramine accelerates the elimination.
Myelotoxic drugs increase the expression gematotoksichnosti drug.
If you have peptic ulcer or gastrointestinal bleeding, the development of side effects of the skin and mucous membranes, the drug should be discontinued.
In patients with decreased blood volume and reduced glomerular filtration (dehydration, congestive heart failure, liver cirrhosis, nephrotic syndrome, symptomatic renal disease, diuretics, andriol testosterone dehydration after major surgery) may cause clinically significant chronic renal failure, which is fully reversible after discontinuation of the drug (in these patients at the beginning of treatment should be monitored daily urine output and renal function). When persistent and substantial increase in transaminases and change others. Liver function parameters drug should be discontinued and conduct control tests.
In patients with an increased risk of side effects, treatment is initiated with a dose of 7.5 mg. In end-stage chronic renal failure patients on hemodialysis, the dose should not exceed 7.5 mg / day.
During the period of treatment must be careful (with the appearance of dizziness and drowsiness) when driving and other lesson. Potentially hazardous activities that require high concentration and psychomotor speed reactions. buy legal anabolic steroids online
best place to buy anabolic steroids online